» Articles » PMID: 33066641

Non-Human Primate Blood-Brain Barrier and In Vitro Brain Endothelium: From Transcriptome to the Establishment of a New Model

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2020 Oct 17
PMID 33066641
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The non-human primate (NHP)-brain endothelium constitutes an essential alternative to human in the prediction of molecule trafficking across the blood-brain barrier (BBB). This study presents a comparison between the NHP transcriptome of freshly isolated brain microcapillaries and in vitro-selected brain endothelial cells (BECs), focusing on important BBB features, namely tight junctions, receptors mediating transcytosis (RMT), ABC and SLC transporters, given its relevance as an alternative model for the molecule trafficking prediction across the BBB and identification of new brain-specific transport mechanisms. In vitro BECs conserved most of the BBB key elements for barrier integrity and control of molecular trafficking. The function of RMT via the transferrin receptor (TFRC) was characterized in this NHP-BBB model, where both human transferrin and anti-hTFRC antibody showed increased apical-to-basolateral passage in comparison to control molecules. In parallel, eventual BBB-related regional differences were investigated in seven-day in vitro-selected BECs from five brain structures: brainstem, cerebellum, cortex, hippocampus, and striatum. Our analysis retrieved few differences in the brain endothelium across brain regions, suggesting a rather homogeneous BBB function across the brain parenchyma. The presently established NHP-derived BBB model closely mimics the physiological BBB, thus representing a ready-to-use tool for assessment of the penetration of biotherapeutics into the human CNS.

Citing Articles

An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family.

Cegarra C, Cameron B, Chaves C, Dabdoubi T, Do T, Genet B PLoS One. 2022; 17(9):e0274667.

PMID: 36108060 PMC: 9477330. DOI: 10.1371/journal.pone.0274667.


Unbound Brain-to-Plasma Partition Coefficient, K-a Game Changing Parameter for CNS Drug Discovery and Development.

Loryan I, Reichel A, Feng B, Bundgaard C, Shaffer C, Kalvass C Pharm Res. 2022; 39(7):1321-1341.

PMID: 35411506 PMC: 9246790. DOI: 10.1007/s11095-022-03246-6.


Exploring ITM2A as a new potential target for brain delivery.

Cegarra C, Chaves C, Deon C, Do T, Dumas B, Frenzel A Fluids Barriers CNS. 2022; 19(1):25.

PMID: 35313913 PMC: 8935840. DOI: 10.1186/s12987-022-00321-3.


Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders.

Lynch M, Gobbo O Nanomaterials (Basel). 2021; 11(10).

PMID: 34685073 PMC: 8538557. DOI: 10.3390/nano11102632.


Characterization of a Primate Blood-Brain Barrier Co-Culture Model Prepared from Primary Brain Endothelial Cells, Pericytes and Astrocytes.

Watanabe D, Nakagawa S, Morofuji Y, Toth A, Vastag M, Aruga J Pharmaceutics. 2021; 13(9).

PMID: 34575559 PMC: 8470770. DOI: 10.3390/pharmaceutics13091484.

References
1.
Nalecz K . Solute Carriers in the Blood-Brain Barier: Safety in Abundance. Neurochem Res. 2016; 42(3):795-809. DOI: 10.1007/s11064-016-2030-x. View

2.
Al Feteisi H, Al-Majdoub Z, Achour B, Couto N, Rostami-Hodjegan A, Barber J . Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels. J Neurochem. 2018; 146(6):670-685. DOI: 10.1111/jnc.14446. View

3.
Molino Y, David M, Varini K, Jabes F, Gaudin N, Fortoul A . Use of LDL receptor-targeting peptide vectors for and cargo transport across the blood-brain barrier. FASEB J. 2017; 31(5):1807-1827. DOI: 10.1096/fj.201600827R. View

4.
Workman M, Svendsen C . Recent advances in human iPSC-derived models of the blood-brain barrier. Fluids Barriers CNS. 2020; 17(1):30. PMC: 7178976. DOI: 10.1186/s12987-020-00191-7. View

5.
Loryan I, Melander E, Svensson M, Payan M, Konig F, Jansson B . In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy. Mol Psychiatry. 2016; 21(11):1527-1536. DOI: 10.1038/mp.2015.229. View